Last reviewed · How we verify
Temozolomide in both arms
At a glance
| Generic name | Temozolomide in both arms |
|---|---|
| Also known as | Temodal |
| Sponsor | Prof. Dr. Wolfgang Wick |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma (PHASE1, PHASE2)
- Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) (PHASE2)
- hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (PHASE2)
- Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma (PHASE1)
- Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (PHASE2)
- Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma (PHASE2)
- Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma (PHASE2)
- A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Temozolomide in both arms CI brief — competitive landscape report
- Temozolomide in both arms updates RSS · CI watch RSS
- Prof. Dr. Wolfgang Wick portfolio CI